Omega Therapeutics, Inc.
OMGA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 49.3% | 1,339.6% | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,028.9% | -150.4% | -863.2% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,021.7% | -4,707% | -44,892.4% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,148.9% | -4,951.1% | -48,029.2% | – |
| EPS Diluted | -1.8 | -2.14 | -1.45 | -0.63 |
| % Growth | 15.9% | -47.6% | -130.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |